FILTER BY:
Details
SW-682 in Advanced Solid Tumors
Address: 1441 Eastlake Ave, Los Angeles, CA 90089, USA
Phone: 877-451-7009
Mesothelioma Type:
- Pleural: True
- Peritoneal: True
- Pericardial: True
- Tunica Vaginalis: True
Type: Epitheliod, Biphasic, Sarcomatoid
Condition: Advanced Solid Tumor, Malignant Mesothelioma
Description: This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.
Research Center: USC/Norris Comprehensive Cancer Center
Treatment Interventions: DRUG: SW-682, DRUG: Combination Therapy
Potential Impact: Low
Clinical Trial Number: NCT06251310
Phase: Phase 1
Status: Recruiting
